Strategic Planning Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$30.7M Buy
25,619
+1,663
+7% +$1.7M 3.35% 9
2026
Q1
$22M Buy
23,956
+15,824
+195% +$16M 3.08% 11
2025
Q4
$8.74M Buy
+8,132
New +$7.78M 1.13% 30
2025
Q3
Sell
-453
Closed -$354K 80
2025
Q2
$354K Sell
453
-7,018
-94% -$5.45M 0.06% 72
2025
Q1
$6.17M Buy
7,471
+632
+9% +$526K 1.21% 25
2024
Q4
$5.28M Buy
6,839
+3,405
+99% +$2.82M 0.97% 30
2024
Q3
$3.04M Buy
3,434
+139
+4% +$125K 0.6% 59
2024
Q2
$2.98M Buy
3,295
+175
+6% +$140K 0.65% 59
2024
Q1
$2.43M Sell
3,120
-588
-16% -$418K 0.61% 56
2023
Q4
$2.16M Buy
+3,708
New +$2.16M 0.72% 48

Other funds holding LLY

Strategic Planning Group's LLY Position: Q2 2026 in Review

Strategic Planning Group increased its Eli Lilly (LLY) stake by 6.9% in Q2 2026, buying an estimated $1.7M and bringing the position to 25,619 shares worth $30.7M. The position accounts for 3.35% of the portfolio, ranked #9.

Strategic Planning Group first reported a position in LLY in Q4 2023 and has held it in 10 quarters since. 1,070 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Strategic Planning Group held 25,619 shares of Eli Lilly worth $30.7M as of Q2 2026.
  • Strategic Planning Group bought 1,663 Eli Lilly shares in Q2 2026, an estimated $1.7M.
  • Eli Lilly made up 3.35% of Strategic Planning Group's portfolio in Q2 2026, its #9 holding.
  • Strategic Planning Group first reported a position in Eli Lilly in Q4 2023 and has held it in 10 quarters since.
  • 1,070 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Strategic Planning Group's 13F filing for Q2 2026, filed 16 Jul 2026.